Evolutionary trends and genetic determinants of third-generation cephalosporin resistance in Escherichia coli from Korean livestock: a 14-year longitudinal study, 2010–2023
Frontiers in Microbiology · 08.05.2026 · 17
DOI: 10.3389/fmicb.2026.1816478 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 08.05.2026. Verfasst von Ji-In Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Bacterial Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs, Gimcheon, Republic of Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The emergence of third-generation cephalosporin-resistant Escherichia coli in livestock is a critical public health concern due to its potential transmission to humans via the food chain. This study investigated the 14-year longitudinal trends (2010–2023) of third-generation cephalosporin resistance, its genetic determinants, and phenotypic characteristics in E. coli isolated from various livestock species in South Korea. Resistance was significantly higher in chickens and pigs than in cattle, with a marked increase observed in healthy chickens over the last decade. A major shift in extended-spectrum beta-lactamase (ESBL) genotypes occurred around 2014, where bla CTX − M−55 emerged as the predominant variant (52.3%, 112/214), surpassing bla CTX − M−14 and bla CTX − M−15 . The majority of isolates (88.8%, 190/214) exhibited multidrug resistance (MDR), frequently involving co-resistance to fluoroquinolones and colistin. These resistance determinants were highly transferable, primarily mediated by IncF and IncI1 plasmids, associated with mobile genetic elements such as IS Ecp1 and IS 26 . Multi-locus sequence typing (MLST) revealed high genetic diversity, with ST752, ST457, and ST10 identified as the most prevalent lineages. Next-generation sequencing (NGS) further confirmed the presence of megaplasmids co-harboring ESBL genes, mcr-1 , metal resistance genes, and diverse virulence factors. These findings highlight a significant evolutionary shift toward bla CTX − M−55 dominance and the rising threat of MDR E. coli in Korean livestock. The high transferability and virulence of these resistance determinants underscore the urgent need for continuous “One Health” surveillance and integrated antimicrobial stewardship to mitigate the risk of zoonotic transmission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bacterial Disease Division, Animal and Plant Quarantine Agency, Ministry of Agriculture, Food and Rural Affairs, Gimcheon, Republic of Korea.
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Seowon-Gu, Cheongju, Republic of Korea.
Zitieren
APA
Kim, J. I., Choi, J. H., Ali, M. S., Moon, B. Y., Kang, H. S., Kim, H. Y., Hwang, Y. J., Lee, Y. H., Kim, M. Y., Kim, J. M., Unno, T., & Lim, S. K. (2026). Evolutionary trends and genetic determinants of third-generation cephalosporin resistance in Escherichia coli from Korean livestock: a 14-year longitudinal study, 2010–2023. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1816478
Vancouver
Kim JI, Choi JH, Ali MS, Moon BY, Kang HS, Kim HY, et al. Evolutionary trends and genetic determinants of third-generation cephalosporin resistance in Escherichia coli from Korean livestock: a 14-year longitudinal study, 2010–2023. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1816478
BibTeX
@article{Kim2026,
author = {Kim, Ji-In and Choi, Ji-Hyun and Ali, Md Sekendar and Moon, Bo-Youn and Kang, Hee-Seung and Kim, Ha-Young and Hwang, Yu-Jeong and Lee, Yeon-Hee and Kim, Min Young and Kim, Jae-Myung and Unno, Tatsuya and Lim, Suk-Kyung},
title = {Evolutionary trends and genetic determinants of third-generation cephalosporin resistance in Escherichia coli from Korean livestock: a 14-year longitudinal study, 2010–2023},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1816478}
}
EUVIMED